Deuterium-Depleted Water for Health & Longevity - Quick Reference Sheet

Deuterium-Depleted Water for Health & Longevity

Created on 06/25/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 Audit

Everyday drinking water with most of its heavy hydrogen removed. The strongest interest is as an add-on in cancer care, with weaker signals for blood-sugar control and animal hints on mood, memory, and aging. It appears safe short-term, but human evidence is thin, unreplicated, and long-term safety is unknown. (Full Review)

Protocol

Concentration
105–125 ppm
Stepwise to progressively lower deuterium concentrations
Daily Volume
~1–1.5 L/day
Used as the primary daily drinking water
Intake Pattern
Spread across the day
Consistent daily intake to hold a lower steady state
Time to effect
Clinical Effects
Months
Claimed clinical effects in studies were assessed over months
Metabolic Reassessment
8–12 weeks
Reassess metabolic endpoints, then every 3–6 months
Body-Water Shift
Days to a few weeks
Body-water deuterium falls with consistent intake

Benefits

Contraindications
  • Replacing or delaying proven therapy for a serious condition
  • Pregnancy and lactation (unstudied)
Key Interactions
  • Conventional cancer therapy (chemotherapy, radiotherapy, hormone therapy)
  • High-dose antioxidants (vitamin C, N-acetylcysteine)
  • Ketogenic diets and fasting

Risk & Side Effects

  • High: [risks_high]
  • Medium: [risks_medium]
  • Low: Opportunity cost and delay of proven care; mild transient symptoms during initiation
  • Speculative: Theoretical effects of sustained deep depletion; unknown long-term safety

Monitoring

Marker Target Why
Fasting glucose 70–85 mg/dL Tracks blood-sugar control, the best-supported metabolic endpoint
Fasting insulin 2–5 µIU/mL Detects insulin resistance, a proposed target of deuterium depletion
HbA1c < 5.4% 3-month average blood sugar; smooths daily variation
hs-CRP < 1.0 mg/L General marker of body-wide inflammation; context for oxidative-stress claims
Disease-specific marker (e.g., PSA in prostate cancer) Per condition Directly tracks the endpoint studied in the relevant trial

Cadence: Reassess metabolic endpoints at ~8–12 weeks, then every 3–6 months; in disease contexts, follow the treating physician's schedule.

Qualitative Assessment

  • Energy levels and perceived fatigue
  • Cognitive clarity and mood
  • Sleep quality and daytime alertness
  • General sense of well-being during the trial period